| Line Item | 2025-09-30 | Y/Y |
|---|---|---|
| Revenue | $8.83B | +11.2% |
| Cost of Revenue | $3.52B | +7.7% |
| Gross Profit | $5.31B | +13.7% |
| R&D Expense | $118.0M | +10.3% |
| SG&A Expense | $945.0M | -3.6% |
| Operating Income | $4.17B | +18.0% |
| Pre-tax Income | $2.63B | +18.7% |
| Income Tax | $555.0M | +11.0% |
| Net Income | $2.07B |
| Line Item | 2025-09-30 | Y/Y |
|---|---|---|
| Cash & Equivalents | $2.81B | -55.2% |
| Accounts Receivable | $1.62B | +17.1% |
| Inventory | $2.10B | +11.7% |
| Current Assets | $7.01B | -30.1% |
| Total Assets | $22.91B | -10.5% |
| Current Liabilities | $2.18B | -65.6% |
| Long-term Debt | $29.29B | +20.1% |
| Line Item | 2025-09-30 | Y/Y |
|---|---|---|
| Operating Cash Flow | $2.04B | -0.3% |
| Capital Expenditures | $222.0M | +34.5% |
| Investing Cash Flow | -$595.0M | +75.6% |
| Financing Cash Flow | -$4.90B | -254.5% |
| Free Cash Flow | $1.82B | -3.4% |
| +21.0% |
| EPS (Basic) | $32.08 | +25.2% |
| EPS (Diluted) | $32.08 | +25.2% |
| Total Liabilities |
| $32.59B |
| +2.3% |
| Stockholders' Equity | -$9.69B | -54.0% |